Peripheral blood stem cells (PBSC) are used for stem cell support in patients after intensive chemotherapy and generally permit faster hematopoietic recovery than bone marrow. The development of different protocols for chemotherapy conditioning, mobilization, and ex vivo manipulation of PBSC may potentially lead t o loss of primitive hematopoietic stem cells or reduction of their quality. To characterize the frequency of different stem cell subsets and their quality per mobilized PBSC, we have studied 47 leukapheresis products (LPs) of 21 cancer patients using stroma-dependent longterm culture (LTC) and limiting dilution-type cobblestone area forming cell (CAFC) assays. A large variation in CAFC week-type frequencies between the LPs was observed. The 
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ERIPHERAL BLOOD stem cells (PBSC) mobilized
after chemotherapy as an alternative source of hematopoietic stem cells (HSC) have been successfully used to rescue cancer patients after intensive chemotherapy requiring stem cell support and to treat hematologic malignancies refractory to standard chemotherapeutic regimen^."^ The finding that HSC are mobilized by hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) has greatly expanded the application of PBSC transplant^.^-'" Moreover, PBSC mobilized by chemotherapy alone or in combination with hematopoietic growth factors have an advantage over bone marrow (BM) transplants because they are associated with a more rapid hematologic and immunologic recovery after myeloablative chemotherapy,4'""z although the reason for this rapid hematologic recovery is still ill-defined. A further optimization of PBSC mobilization for transplantation purposes and the development of ex vivo stem cell manipulation protocols require a study of the quality of mobilized PBSC. As a measure of graft potency, the ability of primitive HSC to produce primi-consistently found in LPs that contained less than 5.000 CAFC week 6 per kilogram of body weight. Frequency analyses of CFCs, CAFC subtypes, and immunophenotypic subsets showed a good level of mutual correlation, suggesting identical mobilization kinetics of different stem cell subsets. The premobilization chemotherapy intensity was directly correlated with both decreasing frequency and quality of the CAFC week 6 in LPs. The frequency of CFCs, immunophenotypic subsets, and CAFC subsets transplanted and the transplant quality as determined in LTC assays was related to the neutrophil and platelet recovery time after PBSC transplantation. Although the number of progenitor cells transplanted and the in vitro transplant quality showed the best correlation with early hematopoietic recovery, the data did not permit determination of which stem cell subsets are predominantly responsible for early posttransplantation recovery. As a result, frequency and quality analysis of stem cell subsets may be a useful tool to monitor and calibrate the efficacy of novel mobilization regimens and ex vivo manipulation of PBSC. 0 1996 by The American Society of Hematology.
tive daughter cells and clonable progenitors over an extended period is determined in stroma-supported long-term culture (LTC) assays."-15 Limiting dilution LTC assays allow frequency analysis of the long-term culture-initiating cell (LTC-IC) by scoring for wells containing replatable colony-forming cells (CFCs) after 5 or 8 weeks of LTC."," Such an assay requires large culture efforts, especially when assessment of frequencies at multiple time points is desired. The development of a human cobblestone area forming cell (CAFC) assay fit for routine use has made it possible to analyze a large series of clinical samples and to determine the frequency of both the 5-fluorouracil-sensitive short-term culture-initiating cell (CAFC week l to 3) and the 5-fluorouracil-resistant LTC-IC (CAFC week 5 to 8) in the same Our first goal was to assess the quantity and quality of stem cells in leukapheresis products (LPs) by determining the frequency of CAFC week-types and the CFC production in parallel LTC and to compare these data with immunophenotypic analyses and data from unmanipulated BM cell samples. Secondly, the effect of premobilization treatment on the CAFC subset content was studied. Finally, by comparing our in vitro data with the short-term in vivo posttransplantation recovery, we attempted to collect data that contribute to validation of the human CAFC assay.
assay.'x MATERIALS AND METHODS

Patients.
Fifteen patients with non-Hodgkin lymphoma, 4 patients with multiple myeloma, l patient with testicular cancer, and 1 patient with Hodgkin disease were included in this study. Before leukapheresis, the patients were treated with several courses of chemotherapy summarized in Table I . Two days after the last course of chemotherapy, G-CSF (Filgrastim, recombinant-methionyl human G-CSF: 5 pgkgld; Roche, Mijdrecht. The Netherlands) was subcuta- neously administered to induce HSC mobilization until the completion of the leukapheresis harvests. PBSC were harvested by leukapheresis once the leukocyte count was greater than 2.0 X 109/L and the percentage of CD34+ cells in the peripheral blood was more than 0.1%. One to three leukaphereses per patient were performed using either a Baxter CS3000+ (Baxter, Utrecht, The Netherlands) or a Cell Separator AS 104 (Fresenius, ' S Hertogenbosch, The Netherlands). In 1 patient (patient no, 9), a suboptimal number of CD34+ cells was harvested (0.15 X 107/kg) after three leukaphereses. Therefore, an additional chemotherapy course was performed and, after G-CSF mobilization, two additional LPs were harvested. After cell collection, any excess of erythrocytes was removed using buffy coat centrifugation. The cells were frozen and stored in liquid nitrogen. The LPs were thawed and reinfused into the patients after myeloablative radio/chemotherapy. All 21 patients received transplants of PBSC without the addition of BM cells; during the hematopoietic recovery, no relapse of disease was observed. In 20 patients, a complete hematopoietic recovery was observed, but 1 patient (patient no. 19) did not show any platelet recovery and was transfusiondependent for more than 1 year after transplantation. Therefore, this patient was not used for the platelet recovery correlation study. The patient characteristics are summarized in Table 1 . Thawed control ampules of each LP were used for the experiments in this study. In total, 47 LPs were studied. From 8 patients the leukaphereses were pooled and subsequently analyzed in the same proportions as transplanted. For the comparison with BM cells, the historic data from 8 normal BM samples" together with 4 additional unmanipulated BM samples from one normal donor and from 1 Hodgkin disease and 2 non-Hodgkin lymphoma patients in remission were used.
Immunojuorescence analysis. CD34 staining was performed by incubating lo6 nucleated cells (NC) after erythrocyte lysis for 30 minutes with anti-CD34-fluorescein isothiocyanate (FITC; anti-HPCA-2 monoclonal antibody; Becton Dickinson, San Jose, CA). For combined CD34 and HLA-DR or CD38 staining, the LPs were incubated in one step for 30 minutes on ice with anti-CD34-FITC and anti-HLA-DR-PE (Becton Dickinson) or anti-CD38-phycoerythrin (PE; Becton Dickinson). The incubations were performed in phosphate-buffered saline (PBS; GIBCO, Breda, The Netherlands) containing 5% fetal calf serum (FCS; Hyclone, Logan, UT). After the incubation, the cells were washed in PBS with 5% FCS and resuspended in 0.5 mL PBS. Analysis was performed using a FACScan (Becton Dickinson). Twenty to thirty thousand events per sample were analyzed. Figure 1 shows the dot plot analysis of one of the LPs with the windows that were used. CAFC analyses with combined CD34-and CD38-sorted LPs have shown that the highest CAFC week 6 to 8 frequencies are found in the CD34+/CD3Sm8 fraction. However, the majority of the late CAFC week 6 to 8 were found in the and CD34+/CD3Sd'* fraction (Ploemacher et al. unpublished observations). Therefore, the percentage of CD34+/CD38*ddi" cells was determined using dot plot lA, window 1. Several investigators have shown that the highest frequency of LTC-IC and late CAFC week 5 and 6 are contained in the CD34+/HLA-DRi0" fraction.16." As a result, in dot plot lB, window 2, the percentage CD34+/HLA-DR'"ce1ls was determined.
Hematopoietic growth factors. For the in vitro studies, the following purified recombinant growth factors were kindly provided: human stem cell factor (SCF) and human G-CSF (Amgen, Thousand Oaks, CA), human GM-CSF and murine SCF (Genetics Institute, 
CD34-FITC fluorescence
Cambridge, MA), and human interleukin-3 (IL-3; Gist Brocades, Delft, The Netherlands).
CFC assay. Quantification of the number of colony-forming units-granulocyte macrophage (CFU-GM) and burst-forming unitserythroid (BFU-E) was performed using a semisolid (1.2% methylcellulose: Methocel, Stade, Germany) culture medium (Iscove's modified Dulbecco's medium [IMDM] ; GIBCO) at 37°C and 5% CO2. The cultures contained 30% FCS supplemented with 0.75% bovine serum albumin (Sigma. St Louis, MO), penicillin ( 1 0 0 U/mL; GIBCO), streptomycin (100 pglmL: GIBCO), P-mercaptoethanol (Pme; 5 X IO" mol/L; Merck, Darmstadt. Germany), erythropoietin ( I UlmL; Boehringer, Mannheim, Germany), IL-3 ( I 5 nglmL), G-CSF (50 ng/mL), GM-CSF (5 nglmL), and human SCF (50 nglmL) or murine SCF ( 1 0 0 nglmL), all at final concentrations. CFU-GM and BFU-E were counted on day 14 of culture in the same dish.
Stromal feeders. The FBMD-I murine stromal cell line was used as described before.'8 Briefly, stromal feeders were prepared by seeding IOs FBMD-I cells from log-phase cultures into 25-cm' culture flasks (Costar, Cambridge, MA) or I O 1 cells per well into flatbottom 96-well plates (Falcon, Lincoln Park, NJ). Culture plastics destined for establishment of FBMD-I stromal feeders were incubated overnight at 4°C with 0.2% gelatin (Sigma) in demineralized water to improve the adherence of the stromal layer. The FBMD-I cells were cultured in IMDM with Glutamax-l (GIBCO) supplemented with penicillin (100 U/mL), streptomycin ( 1 0 0 pg/mL), Dme ( I 0-4 mol/L), 10% FCS, 5% horse serum (HS; GIBCO), and hydrocortisone 21-hemisuccinate (HC: IO-' mol/L: Sigma). After 7 to IO days of culture at 33°C and 10% CO2, the stromal layers had reached confluence and were overlaid with LP cells within the subsequent 2 weeks.
Long-term crtltures injapasks. Confluent stromal layers of FBMD-I cells in 25-cm' flasks were overlaid with 0.50 or 1.0 X IO' LP NC. The cells were cultured in IMDM with Glutamax-l supplemented with penicillin ( 1 0 0 U/mL), streptomycin ( 1 0 0 pg/mL), Dme ( mol/L). 20% HS, and HC (IO-' mol/L). IL-3 (12 nglmL) and G-CSF (20 ng/mL) were added weekly to the cultures. Flask cultures of each LP were set up in duplicate and maintained at 33°C and 10% CO2 for 6 weeks with weekly half-medium changes and therefore removal of only half of the nonadherent (NA) cells. The NA-CFC output of individual flask cultures was determined on weeks 2.4, and 6 and was not corrected for the weekly demidepopulations. At the end of 6 weeks, the number of CFCs in the adherent layer was also determined. To this purpose, the NA cells were collected from the flasks and. after two rinses with PBS, replaced by 3 mL of 0.1 % trypsin-EDTA (GIBCO) at 37°C for 5 minutes. The diges-CD34-FITC fluorescence To diminish the excessive superficial cell production of LPs and consequently increase the visibility of the cobblestone areas, an HC concentration of IO-' mol/L instead of IO"' mol/L was used in the CAFC culture medium. The percentage of wells with at least one phase-dark hematopoietic clone of at least five cells (ie, cobblestone area) beneath the stromal layer was determined weekly for 6 weeks and CAFC frequencies were calculated using Poisson statistics as described Data analysis. Data were analyzed using Slidewrite Plus for DOS-Version 6.0 (Advanced Graphics Software, Carlsbad, CA). To characterize the data, curve fits were performed using a least-squares regression fit. Correlation coefficients for the curve fit ( R ) were calculated. Statistical analysis was performed using GraphPad lnstat (Graphpad Software, San Diego, CA). The Spearman's rank correlation coefficient (rs) was determined to quantitate the degree of linear association between two variables. A two-sided P value was calculated testing the null hypothesis that the population correlation coefficient equals 0. The means of two populations were compared using the Student's t-test. The two-sided P value was determined testing the null hypothesis that the two population means are equal.
RESULTS
CFC production in flask LTC. Thirty-six samples containing 47 LPs of 21 patients were assayed for their content of CFCs and ability to produce NA-CFCs on stromal FBMD-1 feeders in LTC flasks at weeks 2, 4, and 6 after a known input of CFCs. At week 6, the CFC number in the adherent stromal layer was also determined after trypsinization and replating. In Fig 2, the mean CFU-GM, mean BFU-E, and total CFC production in flask LTC of all LPs are shown. As compared with input values (week 0
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of CFU-GM and a decreasing number of BFU-E were harvested from the supernatant during 6 weeks of LTC. At week 6, the stromal layer still contained CFCs and, on average, twofold less than were detected in the supernatant of the same flasks at that time. The dashed lines in Fig 2B showed the maximum and minimum CFC production of the 36 LP samples, which varied greatly for different LPs, showing an up to four-log difference on the basis of the NC input. The ongoing high CFC production that we observed in LPs at 4 weeks and later was at variance with our observation of a declining CFC production by BM samples in LTC, as previously reported."
Frequency analysis of CAFC subsets. Weekly CAFC frequencies of the LPs were determined for 6 weeks. The mean, maximum, and minimum CAFC week-type frequencies of the 36 samples containing 47 LPs of 21 patients were calculated and presented in Fig 3A. Similar to the CFC output in flask LTC, the CAFC frequencies differed among the various patients. The frequencies of CAFC week 2 as a tentative indicator of progenitor cells and transiently repopulating HSC ranged from 0.89 to 205 per lo5 NC, and the frequencies of the primitive CAFC week 6 ranged from 0.37 and 48. However, after a correction of the data for the number of CD34+ cells, these ranges of values were condensed to less than 40-fold difference between the observed ex- Weeks after overlay tremes (Fig 3B) . On average, lower CAFC week 1 through 6 frequencies were found in LPs as compared with BM samples (Table 2) . This difference was larger at early weeks (week 2, 3.7-fold) than at later weeks (week 6, 2.3-fold). Quality analysis of LP and BM as determined using parallel LTC and CAFC assays. In addition to the quantitative estimations of different CAFC week-types, we set out to assess the ability of CAFC to generate CFC in parallel LTC in the same week. Table 3 shows the average number of NA-CFC produced per CAFC weeks 2, 4, and 6 and the number of NA-CFC and stroma-adherent (SA)-CFC per CAFC at week 6 in the 36 LP samples. As compared with BM, an eightfold to 13-fold higher CFC production per CAFC week-type was observed. To compare the quality of primitive HSC in LPs and BM, the total NA-and SA-CFC production in LTC at week 6 was related with the CAFC week 6 frequency (Fig 4) . In BM, any increase in CAFC week 6 frequency was linearly related to a similar increase in CFC production ( R = .74). The average total NA-CFC and SA-CFC production per CAFC at week 6 of BM ranged from 4.2 to 48. In contrast, in LPs, the best curve fit had a logarithmic shape ( R = 3 5 ) . The average total NA-CFC and SA-CFC production per CAFC at week 6 of LPs ranged from 1.2 to 730. In addition, the total NA-CFC and SA-CFC output per CAFC at week 6 as a quality index was related to the total number of CAFC week 6 harvested (Fig 5) . with an absolute yield of less than 5,000 CAFC week 6 harvested per kilogram of body weight expressed an average poor stem cell quality (mean 2 1 SEM: 74 2 31), whereas harvests containing a total of 5,000 or more CAFC week 6 per kilogram of body weight were able to generate a statistically significant (Student's t-test: P = .0071) higher number of CFCs per CAFC at week 6 (mean % l SEM: 252 ? 46). Relation between frequencies of immunophenotypic subsets, CFCs, and CAFC week-types. The percentage of immunophenotypic subsets in the LPs was determined as described in the Materials and Methods (Fig l) . CD34' cell percentages ranged from 0.3 1% to 18%. The percentage of CD34+/CD38""p/di" cells varied between 0.01% and 3.6% and that of CD34+/HLA-DR'"" cells ranged from 0.005% to 2.3%. The degree of linear association between the immunophenotypic subsets, CFCs, and CAFC week-type frequencies in the LPs was quantitated by determining the Spearman's rank correlation coefficient between the variables (Table 4) . CFC frequencies showed a good correlation with CD34' cells (rs = 32, P < .0001), CD34+/CD38""8/d'" cells (rs = .86, P < .OOOl), and all CAFC week-types (rs between .79 and 37, P < .0001). The correlation coefficients between the immunophenotypic subsets and all CAFC week-types were lower but still statistically highly significant (r8 between S 9 and .79, P S .0002).
Effect of premobilization treatment on the CAFC subset content of LPs. Twenty-one chemotherapy-and G-CSFinduced mobilizations were analyzed. Before leukapheresis, the patients received 2 to 16 courses of chemotherapy (Table  1 ). The degree of linear association between the number of premobilization chemotherapy cycles and the mean number of CAFC week-types harvested per kilogram of body weight was quantitated by determining the Spearman's rank correlation coefficient. Figure 6A shows a negative correlation (rs = -.74, P = .OOOl) between the number of chemotherapy cycles and the number of CAFC week 6 harvested. Moreover, all leukaphereses with a low quality of less than 50 NA-CFC and SA-CFC per CAFC at week 6 were harvested from patients who had received at least seven chemotherapy cycles. These observations indicate that the premobilization chemotherapy significantly limits both the number of CAFC that can be mobilized as well as their quality. Figure 6B shows that the negative correlation increased with later CAFC week-types.
Predictive value of in vitro LP analyses for in vivo posttransplantation hematologic recovery. The total number of NC, CD34+ cells, CD34+/CD38"ep/'" cells, CD34'MLA-DR'"" cells, CAFC week-types, and CFC transplanted and total NA-CFC production at weeks 2,4,6, and total combined NA-CFC and SA-CFC production at week 6 in flask LTC of the transplants were related to the posttransplantation time to recover to values of neutrophils greater than 0.5 X 109L (mean ? l SEM: 15 2 1 days; range, 11 to 21 days; n = 21) or platelets greater than 50 X 109/L (mean t l SEM: 19 t 2 days; range, 10 to 52 days; n = 20) of the patients. The Spearman's rank correlation coefficients of the analyses between the different cell subsets are presented in Fig 7. No correlation was found between the number of NC transplanted and the hematopoietic recovery. The number of CD34+ cells, CD34+/CD38"eg'd" cells, CFCs, and CAFC weeks 3 and 4 showed the best correlation, with the recovery time to 0.5 X 109L neutrophils after PBSC transplantation (rs = -S 8 to -.66, P < ,007). However, the number of CAFC weeks 1 and 2 transplanted showed the best relation with the recovery time to 50 X 109L platelets (rs = -.63, P = .0031; and r, = -.59, P = ,0065). The more primitive CAFC week 6 stem cell subset showed a lower correlation with the neutrophil recovery (Y, = -.54, P = .012) and no correlation with the platelet recovery (rs = -.39, P = .092). This suggests that the CAFC week 6 contributes less to early posttransplantation recovery than the less primitive CAFC weeks 1 to 4. Interestingly, the highest correlation was found between the neutrophil recovery and the total transplant quality, as determined in flask LTC (rs = -.67 to -.71, P 5 .0008).
DISCUSSION
The human CAFC assay on the stromal cell line FBMD-1 enables frequency analysis of different stem cell subsets by determining frequencies at multiple time points." The extensively in vivo validated murine CAFC assay strongly For supports the concept that the human CAFC assay can be used as an in vitro frequency analysis of both transiently and long-term repopulating stem cells in However, frequency analysis of stem cell subsets may not suffice to estimate their proliferative ability, eg, in active disease or posttherapy. To allow quality analysis, parallel flask LTC can be included to measure the clonogenic potency per CAFC. In unmanipulated low-density BM samples, the clonogenic potency per HSC shows variation, with means of 4 CFCs per LTC-IC week 5 (range, 1 to 30)"j and 23 CFCs per CAFC at week 6 (range, 4.2 to 48)."
Even more so than in normal BM, the present data show large quantitative and qualitative differences in primitive HSC contained in the analyzed LPs. We observed a mean CAFC week 6 frequency of 10 (range, 0.37 to 48) per lo5
NC and a quality range of 1.2 to 730 NA-CFCs and SACFCs generated per CAFC at week 6. Interestingly, the lowest primitive HSC quality was found in LPs with less than 5,000 CAFC week 6 harvested per kilogram of body weight. The CAFC frequencies observed in our study were within the ranges reported earlier for LP stem cells, ie, 1.8 to 166 NC." However, the extreme variability of progenitor cell generation per CAFC at week 6 contrasted with the low quality of LTC-IC in LPs as reported by Sutherland et aIz5 in a study of 7 patients (ie, 1.1 to 2.7)." These differences may have been caused by the previous treatment and mobilization protocols. Our observations show that stem cell quantification by means of immunophenotyping or CAFCLTC-IC assays does not present information on the proliferative potential of HSC. In addition, the extreme variability in the stem cell quality and quantity between different patients does not permit calculation of HSC frequency by dividing the total CFC output per LTC flask at week 5 by an average CFC output per stem cell (ie, 4), as proposed by the Vancouver Because all frequency determinations have been performed with unsorted cell fractions, this can partly explain the high correlation between the various immunophenotypic subsets, CFCs, and CAFC week-types. It also suggests that different stem cell subsets were mobilized with comparable kinetics and extend in these patients. A statistically highly significant negative correlation was found between the number of chemotherapy cycles and the number of CAFC week 6 harvested. Haas et aI2' recently reported a similar relation between chemotherapy cycles and the number of CD34+ cells harvested. Furthermore, all leukaphereses with a low quality of less than 50 NA-CFCs and SA-CFCs per CAFC at week 6 were harvested from patients who had received at least seven chemotherapy cycles. This observation shows that not only quantity but also quality of HSC is affected by consecutive courses of Chemotherapy. Interestingly, the negative correlation increased with later CAFC week-types, suggesting that the primitive HSC compartment is most affected by chemotherapy.
As reported by other investigators,4.11,27 the hematologic recovery showed a good correlation with the number of CFCs or CD34+ cells transplanted. The present data also suggest that a correlation exists between the neutrophil recovery and the number of CD34+/CD38""g'di" cells and CAFC week 3 and 4. The number of CAFC weeks 1 and 2 transplanted showed the best relation with the platelet recovery. These data may suggest a role of these stem cell subsets 300 P=0.0071 in early neutrophil and platelet recovery. However, other CAFC subsets correlate with early hematopoietic recovery as well. Therefore, it will be very difficult to prove which stem cell subset is predominantly involved in early neutro- CAFC week-type harvested to 52 days; n = 20) of the patients were quantitated with the Spearman's rank correlation coefficient. Twosided P value: * P < .05; **P < .01; * * * P < .001. phi1 and platelet recovery, unless marked or sorted stem cell subsets are used in the transplants, as has been done in animal neutrophil recovery and the total transplant quality as determined in flask LTC indicates that not only the number of HSC transplanted but also the quality of the transplant contributes to the hematopoietic recovery.
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